A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients

American Journal of Transplantation

Volumn 14, Issue 9, 2014, Pages 2106-2119

  Lim, W H ^a,b   Eris, J ^c   Kanellis, J ^d   Pussell, B ^e   Wiid, Z ^f   Witcombe, D ^f   Russ, G R ^g  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d MONASH MEDICAL CENTRE   (Australia)

^e PRINCE OF WALES HOSPITAL   (Australia)

^f PFIZER INC   (United States)

^g ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Clinical research; dysfunction; immune modulation; immunosuppression; immunosuppressive regimens; kidney (allograft) function; kidney transplantation; maintenance; meta analysis; minimization; nephrology; practice; withdrawal

Indexed keywords

CALCINEURIN INHIBITOR; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENTION TO TREAT ANALYSIS; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SKIN CANCER; SYSTEMATIC REVIEW; ANTAGONISTS AND INHIBITORS;

CALCINEURIN INHIBITORS; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; TOR SERINE-THREONINE KINASES;

EID: 84906246466     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12795     Document Type: Review

References (55)

1. Wolfe R, Ashby V, Milford E, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725-1730.
2. Clayton P, Campbell S, Hurst K, McDonald S, Chadban S., Transplantation. Adelaide, Australia: Australia and New Zealand Dialysis and Transplant Registry, 2011.
3. Pilmore H, Dent H, Chang S, McDonald S, Chadban S., Reduction in cardiovascular death after kidney transplantation. Transplantation 2010; 89: 851-857.
4. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi A., Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580-590.
5. Pascual J, Pérez-Sáez M, Mir M, Crespo M., Chronic renal allograft injury: Early detection, accurate diagnosis and management. Transplant Rev (Orlando) 2012; 26: 280-290.
6. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR., The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
7. Diekmann F, Campistol JM., Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: Benefits and risks. Nephrol Dial Transplant 2006; 21: 562-568.
8. Kasiske BL, Chakkera HA, Louis TA, Ma JZ., A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910-1917.
9. Ekberg H, Grinyo J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study. Am J Transplant 2007; 7: 560-570.
10. Abramowicz D, Del Carmen Rial M, Vitko S, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: Results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005; 16: 2234-2240.
11. Chadban S, Morris R, Hirsch HH, Bunnapradist S, Arns W, Budde K., Immunosuppression in renal transplantation: Some aspects for the modern era. Transplant Rev (Orlando) 2008; 22: 241-251.
12. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575.
13. Webster A, Lee V, Chapman J, Craig J., Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234-1248.
14. Russ G, Segoloni G, Oberbauer R, et al. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation 2005; 80: 1204-1211.
15. Flechner S, Glyda M, Cockfield S, et al. The ORION study: Comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011; 11: 1633-1644.
16. Buchler M, Caillard S, Barbier S, et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7: 2522-2531.
17. Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T., Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three-year phase II, randomized, multicenter, open-label study. Transplantation 2004; 78: 1332-1340.
18. Tedesco-Silva H Jr, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010; 10: 1401-1413.
19. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: Concept study. Am J Transplant 2009; 9: 1115-1123.
20. Duerr M, Naik M, Schmidt D, Neumayer H, Budde K., Higher rates of acute rejections despite enhanced rates of regulatory T cells under mTOR inhibitor therapy in renal transplant patients. Am J Transplant 2012; 12: A301.
21. Smith MP, Newstead CG, Ahmad N, et al. Poor tolerance of sirolimus in a steroid avoidance regimen for renal transplantation. Transplantation 2008; 85: 636-639.
22. Ruiz J, Sánchez Fructuoso A, Hernández D, et al. Better renal function with early everolimus (Evl) introduction and calcineurin inhibitor (CNI) withdrawal at third month in kidney recipients at month 12: Results of the ERIC Study. Transplant Int 2011; 24: A112.
23. Heilman RL, Younan K, Wadei HM, et al. Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal. Transplantation 2011; 92: 767-773.
24. Budde K, Witzke O, Lehner F, et al. Superior renal function in an everolimus-based calcineurin inhibitor free regimen compared to standard cyclosporine/mycophenolate and low cyclosporine/everolimus: The HERAKLES Study. Am J Transplant 2012; 12: A50.
25. Van der Heide J, de Fijter J, ten Berge I, de Maar E, Bemelman F., MECANO: Mycophenolate sodium vs everolimus or cyclosporin with allograft nephropathy as outcome study: Clinical results. Transplant Int 2011; 24: A85.
26. Mjornstedt L, Sorensen SS, von Zur Muhlen B, et al. Improved renal function after early conversion from a calcineurin inhibitor to everolimus: A randomized trial in kidney transplantation. Am J Transplant 2012; 12: 2744-2753.
27. Pankewycz O, Leca N, Kohli R, et al. Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: A prospective, protocol biopsy-guided study. Transplant Proc 2011; 43: 519-523.
28. Seckinger J, Sommerer C, Hinkel U, Hoffmann O, Zeier M, Schwenger V., Switch of immunosuppression from cyclosporine A to everolimus: Impact on pulse wave velocity in stable de-novo renal allograft recipients. J Hypertens 2008; 26: 2213-2219.
29. Guba M, Pratschke J, Hugo C, et al. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: One-year analysis of a randomized multicenter trial. Transplantation 2010; 90: 175-183.
30. Chadban S, Eris J, Kanellis J, et al. A randomized, controlled trial of everolimus based dual immunosuppression vs standard of care in de novo kidney transplant recipients. Transplant Int 2013; doi: 10.1111/tri.12252 [Epub ahead of print].
31. Tedesco H, Garcia V, David-Neto E, et al. Conversion from tacrolimus (TAC) to sirolimus (SRL)-based immunosuppressive regimen in kidney transplant recipients: 1 Year results. Am J Transplant 2012; 12: A299.
32. Tedesco-Silva H, Peddi V, Sanchez-Fructoso A, et al. Interim results from an open-label study of planned transition from tacrolimus to sirolimus vs continued tacrolimus in renal allograft recipients: Cardiovascular safety: 1749. Transplantation 2012; 94: A142.
33. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin- inhibitor-free regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial. Lancet 2011; 377: 837-847.
34. Budde K, Sommerer C, Haller H, et al. Renal function of an everolimus based therapy after calcineurin inhibitor withdrawal in maintenance renal transplant recipients: 2 Year data of the APOLLO trial. Am J Transplant 2011; 11: 411.
35. Holdaas H, Rostaing L, Seron D, et al. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: A randomized, multicenter, 24-month study. Transplantation 2011; 92: 410-418.
36. Baboolal K, Zaiac M, Zamauskaite A, Newstead C., This multicentre, randomised study comparing conversion from calcineurin inhibitors (CNIs) to sirolimus versus standard therapy in renal allograft recipients showed a lower rate of development of subsequent malignant disease in the group receiving sirolimus. Am J Transplant 2009; 9: A238.
37. Schena F, Pascoe M, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-Month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233-242.
38. Han F, Wu J, Huang H, et al. Conversion from cyclosporine to sirolimus in chronic renal allograft dysfunction: A 4-year prospective study. Exp Clin Transplant 2011; 9: 42-49.
39. Hendrikx TK, Velthuis JH, Klepper M, et al. Monotherapy rapamycin allows an increase of CD4 CD25 FoxP3 T cells in renal recipients. Transplant Int 2009; 22: 884-891.
40. Kihm LP, Hinkel UP, Michael K, et al. Contrast enhanced sonography shows superior microvascular renal allograft perfusion in patients switched from cyclosporine A to everolimus. Transplantation 2009; 88: 261-265.
41. Liu M, Zhang W, Gu M, et al. Protective effects of sirolimus by attenuating connective tissue growth factor expression in human chronic allograft nephropathy. Transplant Proc 2007; 39: 1410-1415.
42. Weir M, Mulgaonkar S, Chan L, et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: A randomized, controlled spare-the-nephron trial. Kidney Int 2011; 79: 897-907.
43. Stallone G, Infante B, Schena A, et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005; 16: 3755-3762.
44. Watson CJ, Firth J, Williams PF, et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 2005; 5: 2496-2503.
45. Campbell S, Walker R, Tai S, Jiang Q, Russ G., Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 2012; 12: 1146-1156.
46. Pontrelli P, Rossini M, Infante B, et al. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation 2008; 85: 125-134.
47. Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012; 367: 329-339.
48. Gurkan A, Kacar S, Erdogdu U, et al. The effect of sirolimus in the development of chronic allograft nephropathy. Transplant Proc 2008; 40: 114-116.
49. Maiorano A, Stallone G, Schena A, et al. Sirolimus interferes with iron homeostasis in renal transplant recipients. Transplantation 2006; 82: 908-912.
50. Cataneo-Davila A, Zuniga-Varga J, Correa-Rotter R, Alberu J., Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination. Transplant Proc 2009; 41: 4138-4146.
51. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
52. Cockcroft DW, Gault MH., Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
53. Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D., A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
54. Nankivell BJ, Gruenewald SM, Allen RD, Chapman JR., Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683-1689.
55. Kasiske BL, Israni AK, Snyder JJ, Skeans MA., The relationship between kidney function and long-term graft survival after kidney transplant. Am J Kidney Dis 2011; 57: 466-475.